The anti-profiteering authority has found Abbott Healthcare guilty of not passing on the benefit of GST rate reduction to the tune of Rs 96.59 lakh to consumers and asked the Mumbai-based company to deposit the amount in the consumer welfare fund.
While investigating a complaint, the Directorate General of Anti Profiteering found the company had not passed on the GST rate cut benefit while selling "Melaglow Rich (Niainamide) Depigmentation & Glow Restoration Cream".
The tax rate on the product, which was 30.06 per cent in the pre-GST regime, was reduced to 28 per cent with the rollout of the goods and services tax from July 1, 2017, and further to 18 per cent with effect from November 15, 2017.
However, during these periods, the base price of the product was increased from Rs 202.06 to Rs 230.90 per unit which resulted in an increase of the selling price and denial of passing the benefit of tax reduction to the customers.
"Thus the total amount the benefit of which was denied to the recipients by Respondent No 1 (Abbott Healthcare Pvt Ltd) or the profiteered amount during the period w.e.f July 1, 2017 to July 31, 2018, comes to Rs 96,59,716.26," the National Anti-Profiteering Authority (NAA) said in its order.
The NAA directed the company to deposit the profiteered amount to the Consumer Welfare Fund of the Centre and states, along with 18 per cent interest.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
